High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 4 years
Technicals: Bullish SharesGuru indicator.
Buy Backs: Company has bought back it's stock in the past which is a good thing.
Profitability: Very strong Profitability. One year profit margin are 23%.
Size: It is among the top 200 market size companies of india.
Growth: Good revenue growth. With 36.4% growth over past three years, the company is going strong.
Balance Sheet: Strong Balance Sheet.
Smart Money: Smart money has been increasing their position in the stock.
Past Returns: Outperforming stock! In past three years, the stock has provided 23.9% return compared to 7.6% by NIFTY 50.
Momentum: Stock is suffering a negative price momentum. Stock is down -2.8% in last 30 days.
Valuation | |
|---|---|
| Market Cap | 1.76 LCr |
| Price/Earnings (Trailing) | 68.45 |
| Price/Sales (Trailing) | 15.89 |
| EV/EBITDA | 45.35 |
| Price/Free Cashflow | 806.51 |
| MarketCap/EBT | 51.89 |
| Enterprise Value | 1.76 LCr |
Fundamentals | |
|---|---|
| Revenue (TTM) | 11.07 kCr |
| Rev. Growth (Yr) | 11.8% |
| Earnings (TTM) | 2.57 kCr |
| Earnings Growth (Yr) | 13.4% |
Profitability | |
|---|---|
| Operating Margin | 31% |
| EBT Margin | 31% |
| Return on Equity | 15.32% |
| Return on Assets | 12.82% |
| Free Cashflow Yield | 0.12% |
Growth & Returns | |
|---|---|
| Price Change 1W | -0.50% |
| Price Change 1M | -2.8% |
| Price Change 6M | 3.6% |
| Price Change 1Y | -0.40% |
| 3Y Cumulative Return | 23.9% |
| 5Y Cumulative Return | 8.8% |
| 7Y Cumulative Return | 22.7% |
| 10Y Cumulative Return | 19.2% |
Cash Flow & Liquidity | |
|---|---|
| Cash Flow from Investing (TTM) | -2.22 kCr |
| Cash Flow from Operations (TTM) | 2.74 kCr |
| Cash Flow from Financing (TTM) | -804 Cr |
| Cash & Equivalents | 128 Cr |
| Free Cash Flow (TTM) | 218 Cr |
| Free Cash Flow/Share (TTM) | 8.21 |
Balance Sheet | |
|---|---|
| Total Assets | 20.03 kCr |
| Total Liabilities | 3.27 kCr |
| Shareholder Equity | 16.76 kCr |
| Current Assets | 11.1 kCr |
| Current Liabilities | 2.04 kCr |
| Net PPE | 6.51 kCr |
| Inventory | 3.95 kCr |
| Goodwill | 0.00 |
Capital Structure & Leverage | |
|---|---|
| Debt Ratio | 0.00 |
| Debt/Equity | 0.00 |
| Interest Coverage | 146.3 |
| Interest/Cashflow Ops | 120.04 |
Dividend & Shareholder Returns | |
|---|---|
| Dividend/Share (TTM) | 30 |
| Dividend Yield | 0.49% |
| Shares Dilution (1Y) | 0.00% |
| Shares Dilution (3Y) | 0.00% |
High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 4 years
Technicals: Bullish SharesGuru indicator.
Buy Backs: Company has bought back it's stock in the past which is a good thing.
Profitability: Very strong Profitability. One year profit margin are 23%.
Size: It is among the top 200 market size companies of india.
Growth: Good revenue growth. With 36.4% growth over past three years, the company is going strong.
Balance Sheet: Strong Balance Sheet.
Smart Money: Smart money has been increasing their position in the stock.
Past Returns: Outperforming stock! In past three years, the stock has provided 23.9% return compared to 7.6% by NIFTY 50.
Momentum: Stock is suffering a negative price momentum. Stock is down -2.8% in last 30 days.
Investor Care | |
|---|---|
| Dividend Yield | 0.49% |
| Dividend/Share (TTM) | 30 |
| Shares Dilution (1Y) | 0.00% |
| Earnings/Share (TTM) | 96.75 |
Financial Health | |
|---|---|
| Current Ratio | 5.43 |
| Debt/Equity | 0.00 |
Technical Indicators | |
|---|---|
| RSI (14d) | 30.14 |
| RSI (5d) | 42.35 |
| RSI (21d) | 43.45 |
| MACD Signal | Sell |
| Stochastic Oscillator Signal | Hold |
| SharesGuru Signal | Buy |
| RSI Signal | Hold |
| RSI5 Signal | Hold |
| RSI21 Signal | Hold |
| SMA 5 Signal | Sell |
| SMA 10 Signal | Sell |
| SMA 20 Signal | Sell |
| SMA 50 Signal | Buy |
| SMA 100 Signal | Buy |
Summary of Divi's Lab's latest earnings call, featuring management's outlook on business performance, financial results, and analyst Q&A sessions that highlight key strategic initiatives and market challenges.
During the earnings call held on February 11, 2026, management provided a positive outlook for Divi's Laboratories, emphasizing their commitment to operational reliability and capacity expansion. The key forward-looking points include:
Financial Performance: For Q3 FY2026, the consolidated total income was Rs.2,692 crores, up from Rs.2,401 crores year-over-year. The profit before exceptional items and tax increased to Rs.854 crores from Rs.726 crores in Q3 FY2025.
Future Growth: Management anticipates that several projects in the Custom Synthesis (CS) segment will reach commercial volumes within the next year, contributing positively to revenue.
Capacity Utilization: Currently, the company operates at a capacity utilization of 70% to 80%. As new projects either complete validations or secure regulatory approvals, the company will adapt its capacity accordingly.
Nutraceuticals: The company expects continued momentum in their Nutraceuticals division, marking 20 years of operations in this segment and expanding capacity.
Project Timelines: Management expects that three dedicated custom synthesis projects should begin commercial volumes by late 2027, pending regulatory approvals.
Cost Management: The firm reported improved material consumption for Q3 FY2026 at 36.3%, down from 39.8% year-over-year, highlighting better cost efficiencies.
Raw Material Stability: Management noted that raw material costs remain stable, although they are cautious about potential impacts from policy changes such as China's withdrawal of export rebates, which might affect pricing dynamics in the market.
Cash Position: The company maintained a strong cash position with cash and cash equivalents at Rs.3,686 crores, supporting future growth initiatives.
These points illustrate management's focus on sustaining growth, enhancing operational efficiencies, and navigating market challenges effectively.
Question 1: "What is the capacity buildup that we are doing on GLP-1s? Can you give some update?"
Answer: We have completed the construction of a pilot plant and a commercial building with large-scale SPPS designed for a customer's requirements. Currently, validations are ongoing after the pilot work. I'm unable to disclose specific capacity numbers, but these developments are crucial for our strategy.
Question 2: "Are any of the three dedicated custom synthesis facilities related to peptides?"
Answer: I can't comment specifically on the projects, but they encompass a mix of all types of chemistry, not limited to peptides.
Question 3: "What is the capacity utilization and progress on new opportunities regarding contrast media?"
Answer: Our capacity utilization is between 70% to 80%. Validations for multiple products are in progress; once complete, we'll begin commercialization. Capacity adjustments will be made as needed based on customer regulatory approvals.
Question 4: "Any opportunities identified from the India-EU FTA?"
Answer: It's premature for us to comment, as the agreement was just finalized recently.
Question 5: "Can you elaborate on the molecules going to commercial volumes within the CS segment in the next year?"
Answer: Once validations are completed and regulatory approvals obtained, we will discuss volumes for commercialization. This will depend on the completion of specific validations and customer requirements.
Question 6: "How much of the business exposure do you hedge?"
Answer: Currently, we are not hedging our exposures and are assessing market conditions.
Question 7: "Can you explain the sharp improvement in gross margins?"
Answer: The improvement is primarily due to product mix changes, with a stronger performance from the Custom Synthesis segment this year as compared to last.
Question 8: "What proportion of the commercialized molecules are already approved versus new ones?"
Answer: I cannot disclose specifics due to confidentiality agreements. Generally, we work across several stages of the product lifecycle with our clients.
Question 9: "When should we expect commissioning of the dedicated capex capacity?"
Answer: We anticipate starting to see commercialization by the end of 2027 after customer approvals.
Question 10: "What is the impact of China's withdrawal of export rebates on your operations?"
Answer: While we must remain cautious, we have diversified our procurement sources to mitigate impacts, with 78% of our materials now sourced domestically.
Question 11: "What is the status of Unit 3 in terms of supporting backward integration?"
Answer: Unit 3 has been instrumental in supporting Units 1 and 2, with capacity enhancements ongoing as we revamp existing facilities. Future approvals and products will dictate how we progress further.
Understand Divi's Lab ownership landscape with insights into key distribution patterns, offering investors a clear view of stakeholder dynamics.
| Shareholder Name | Holding % |
|---|---|
| SATCHANDRA KIRAN DIVI | 20.34% |
| NILIMA PRASAD DIVI | 20.34% |
| SWARNA LATHA DIVI | 5.27% |
| SBI MUTUAL FUND | 4.21% |
| GOVERNMENT OF SINGAPORE | 3.89% |
| DIVI'S BIOTECH PRIVATE LIMITED | 3.01% |
| MURALI KRISHNA PRASAD DIVI | 2.85% |
| LIFE INSURANCE CORPORATION OF INDIA | 2.79% |
| HDFC MUTUAL FUND | 2% |
| AXIS MUTUAL FUND TRUSTEE LIMITED | 1.37% |
| NIPPON LIFE INDIA TRUSTEE LTD | 1.34% |
| GOVERNMENT PENSION FUND GLOBAL | 1.27% |
| MADHUSUDANA RAO DIVI | 0.06% |
| RADHAKRISHNA RAO DIVI | 0% |
Distribution across major stakeholders
Distribution across major institutional holders
Detailed comparison of Divi's Lab against industry peers, highlighting key financial metrics, valuation ratios, and performance indicators to provide competitive context within the sector.
Ticker | Name | Mkt Cap | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
|---|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | Sun Pharmaceutical Industries | 4.29 LCr | 60.43 kCr | -3.20% | +6.50% | 37.42 | 7.1 | - | - |
| CIPLA | Cipla | 1.12 LCr | 29.04 kCr | +3.00% | -7.70% | 28.89 | 3.86 | - | - |
| DRREDDY | Dr. Reddy's Lab | 1.07 LCr | 35.06 kCr | -1.40% | -3.40% | 25.36 | 3.04 | - | - |
| LUPIN | Lupin | 1.03 LCr | 28.38 kCr | -5.20% | +12.80% | 19.31 | 3.63 | - | - |
| AUROPHARMA | Aurobindo Pharma | 84.32 kCr | 34.18 kCr | -2.40% | +25.00% | 24.06 | 2.47 | - | - |
| LAURUSLABS | Laurus Labs | 75.83 kCr | 6.87 kCr | +14.40% | +118.80% | 85.29 | 11.04 | - | - |
Comprehensive comparison against sector averages
DIVISLAB metrics compared to Pharmaceuticals
| Category | DIVISLAB | Pharmaceuticals |
|---|---|---|
| PE | 68.45 | 35.88 |
| PS | 15.89 | 4.94 |
| Growth | 13.9 % | 10.7 % |
Divi's Lab is a prominent Pharmaceuticals company, trading under the stock ticker DIVISLAB. With a significant market capitalization of Rs. 160,290.2 Crores, the company specializes in the manufacture and sale of generic active pharmaceutical ingredients (APIs), intermediates, and nutraceuticals, catering to diverse markets including India, North America, Asia, and Europe.
The company not only produces its own goods but also engages in custom synthesis contract manufacturing services for APIs and intermediates. Additionally, Divi's Lab supplies various carotenoids, such as beta carotene, astaxanthin, lycopene, and canthaxanthin, along with other finished products like lutein and vitamins, primarily serving industries involved in food, dietary supplements, and feed manufacturing.
Founded in 1990 and based in Hyderabad, India, Divi's Lab was initially known as Divi's Research Center until it rebranded in 1994. Over the past year, the company has reported a trailing revenue of Rs. 9,424 Crores, alongside a profit of Rs. 2,067 Crores in the last four quarters.
Divi's Lab actively pays dividends to its investors, currently offering a dividend yield of 1.01% per year, with a reported dividend of Rs. 60 per share in the last 12 months. The company has exhibited robust performance, achieving a revenue growth of 13.2% over the past three years, reinforcing its status as a profitable entity in the pharmaceutical sector.
This is an informational page just to provide a quick 'first look' at the stock. You must do your own deeper research. Know your risk appetite. Consult a SEBI-registered financial advisor before making any investment decisions.
DIVISLAB vs Pharmaceuticals (2021 - 2026)